DPP4 inhibitors preserve the activity of CXCL10 and make biologically active CXCL10 interact with its ligand (CXCR3) on NK and T cells, thereby increasing the chemotaxis of NK and T cells and further inhibiting tumor growth. This evidence concerns the gene CXCL10 and neoplasm.